The US Court of Appeals for the Federal Circuit in Washington affirmed a lower court ruling that let Watson enter the market even as it awaits the outcome of a patent-infringement lawsuit filed by Teva’s Duramed unit.
Watson began selling a generic version of Teva’s Seasonique contraceptive in July. Teva contends the copy infringes a patent that expires in January 2024, and sought to block sales until a trial on the validity of the patent.
Seasonique generated $110 million in sales in the 12 months ending April 30, New Jersey-based Watson said in July, citing IMS Health data.
Teva's share price fell 0.2% on Nasdaq on Friday to $40.52, giving a market cap of $35.9 billion, and fell 1.6% in early trading on the TASE to NIS 151.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments